Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 45,506

Document Document Title
WO/2013/166295
Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.  
WO/2013/165140
The present invention relates to: a benzyl derivative containing an activated vinyl group; a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the compound as an active ingredient. The benzyl derivativ...  
WO/2013/165481
A novel product for headache relief and use of the product to treat headaches is disclosed herein. The product may be applied topically, and may be used for acute treatment of headaches to provide a safe, effective, and natural alternati...  
WO/2013/164794
The present invention relates to crystalline forms of vilazodone hydrochloride designated as Form A, Form B, and Form C, and processes for their preparation.  
WO/2013/166413
A pharmaceutical composition is provided which includes a pharmaceutically acceptable excipient and a pharmaceutically and physically acceptable amount of a compound selected from the group consisting of Chemical Formulas I-IV as describ...  
WO/2013/164321
Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.  
WO/2013/166246
A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet anot...  
WO/2013/164561
There is described a sub-analgesic amount of tramadol, or a salt thereof, in the treatment, alleviation or prevention of depression in a patient wherein the sub- analgesic amount is from about 60 to 80mg, of tramadol or a salt thereof.  
WO/2013/166438
Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as...  
WO/2013/164730
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R1 and R2 are as defined in the specification. Corresponding pharma...  
WO/2013/166030
Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing ...  
WO/2013/166413
A pharmaceutical composition is provided which includes a pharmaceutically acceptable excipient and a pharmaceutically and physically acceptable amount of a compound selected from the group consisting of Chemical Formulas I-IV as describ...  
WO/2013/166438
Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as...  
WO/2013/164323
Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated wit...  
WO/2013/165575
The invention relates to fluorinated compounds and their use as anti-epileptic, muscle- relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl car...  
WO/2013/159151
The present invention comprises both meloxicam and xylazine containing compositions and methods of their administration in the field of veterinary pharmaceuticals. A meloxicam and xylazine formulation is provided which is adapted for ora...  
WO/2013/161913
Provided is a compound which has a selective inhibitory activity on PDE2A and is useful as a prophylactic/therapeutic agent for schizophrenia, Alzheimer's disease or the like. A compound represented by formula (1) [wherein each symbol is...  
WO/2013/162363
The current invention provides an improved oligonucleotide and its use for treating, ameliorating, preventing, delaying and/or treating a human cis-element repeat instability associated genetic neuromuscular or neurodegenerative disorder.  
WO/2013/161312
The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which ...  
WO/2013/161993
The present invention pertains to: a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof; and a drug containing the compound as the active ingredient. Specifically, the trans-2-decenoic acid derivative or...  
WO/2013/159412
A method for extracting and separating ginkgolides. The ginkgolides obtained through steps of extraction on a ginkgo leaf, further extraction, column chromatography, crystallization, and crystal mixing comprise 25.0% to 50.0% of bilobali...  
WO/2013/162050
The purpose of the invention is to provide: a lactoferrin fusion protein that retains the bioactivity of natural lactoferrin, significantly prolongs the in vivo lifespan, and has better clinical utility than natural lactoferrin and recom...  
WO/2013/162046
An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-y1-piperazin-...  
WO/2013/161919
The purpose of the present invention is to provide is a drug the active ingredient of which is a compound that has Trk-inhibiting activity in the prevention and/or treatment of diseases such as pain, pruritus, lower urinary tract disorde...  
WO/2013/163402
Subjects that have a 16p11.2 microdeletion syndrome are treated by administering compositions that include mGluR inhibitors, including mGluR antagonists that include mGluR negative allosteric modulators. Administration of compositions em...  
WO/2013/163562
The invention described herein pertains to compositions and methods for treating PTSD and related diseases. In particular, the invention described herein pertains to compositions and methods for treating PTSD and related diseases by admi...  
WO/2013/162413
The invention relates to the field of pharmacology and clinical medicine and concerns a pharmaceutical composition of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form and/or in the form of a pharmaceutically acceptable ...  
WO/2013/162048
An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention i...  
WO/2013/159411
A ginkgolide injection and a preparation method thereof. The injection comprises the following components: 1-10 mg/ml of ginkgolide (counted based on terpene lactone), 0.2-0.5 ml/ml of glycerol, 0.4-0.7 ml/ml of ethanol, and 0-0.5 ml/ml ...  
WO/2013/161471
The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof.  
WO/2013/160728
Compounds of formula (I) wherein the groups are as defined in the description, are used as medicaments, in particular for the treatment of a disease selected from the group consisting of: cognitive impairment, memory dysfunction, neurode...  
WO/2013/163142
The prevent invention relates to a liquid pharmaceutical composition for treating a patient having moderate to severe pain. The liquid pharmaceutical composition comprises an effective amount of ketorolac or ketorolac tromethamine, and a...  
WO/2013/163455  
WO/2013/161816
The present invention provides a compound represented by general formula (I) [wherein each symbol is as defined in the description], which has an excellent peripheral blood lymphocyte-reducing activity and is useful for the treatment or ...  
WO/2013/161823
Provided are: an orally disintegrating tablet that disintegrates rapidly when held in the mouth or when placed in water, is palatable, possesses ample hardness for during normal production, transport, and use, and has excellent storage s...  
WO/2013/161308
The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gate...  
WO/2013/160273
The present invention is concerned with a novel process for the preparation of a compound of formula I and its hydrates, as well as with a crystall polymorph thereof. The compounds of formula (I) and the corresponding hydrates are pharma...  
WO/2013/162757
The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as CDM-Hs, function through orthogonal pathways, by inhibiting the gp120-CD4...  
WO/2013/161928
Disclosed is the compound represented by formula (I) or a pharmaceutically acceptable salt thereof (in the formula: R1a is a hydrogen atom or the like; R7 is the group represented by -C(R3a)(R4a)-N(R5a)-Y­ a-R6a or the like; R3a and R4a...  
WO/2013/160896
The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereo...  
WO/2013/162027
The present invention provides a neuronal differentiation promoter for a neural stem cell, which comprises a p38 inhibitor. The present invention also provides a method for promoting the neuronal differentiation of a neural stem cell, wh...  
WO/2013/161929
Disclosed is the compound represented in formula (I) or a pharmaceutically acceptable salt of same (in the formula: R1 is an aromatic carbon ring group or the like; -X- is a single bond, -O(C(R5a)(R5b))p- or the like; R5a and R5b are hyd...  
WO/2013/161871
Provided is a novel compound that inhibits at least one selected from the group consisting of TLR3, TLR7, and TLR9 and has excellent preventive and therapeutic activity against autoimmune disease, inflammation, allergy, and the like. The...  
WO/2013/163576
The present disclosure relates to pantothenate derivatives for the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in trea...  
WO/2013/163214
A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker, where the dosing regimen provides a prolonged nerve block and is in an effective amount to delay the onset of neuropathic pain, such ...  
WO/2013/160885
The present disclosure is in relation to a composition comprising nanosphere and histone acetyltransferase (HAT) activator. The disclosed nanosphere is carbon nanosphere (CSP) which is intrinsically fluorescent and the HAT activator is N...  
WO/2013/162061
Provided is a novel compound which inhibits Axl, and is useful in the treatment of diseases caused by Axl hyperfunction, the treatment of diseases related to Axl hyperfunction, and/or the treatment of diseases which accompany Axl hyperfu...  
WO/2013/155714
Disclosed is a heart rejuvenating capsule, which is prepared by mixing Poria, Ganoderma lucidum, milkvetch root, Radix Acanthopanacis Senticosi and Pearl and then putting the mixture into a capsule. The capsule is rich in nutrition, has ...  
WO/2013/156782
The present invention relates to the new use of the compound 3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H- 2-benzopyran for the treatment of diseases or conditions that are associated with β-amyloid induced toxicity, such...  
WO/2013/157555
The invention provides an aplysiatoxin derivative represented by formula (I), or a pharmaceutically acceptable salt thereof, that is a PKC activator having no carcinogenesis-promoting activity that can serve as an alternative to Bryo-1 a...  

Matches 501 - 550 out of 45,506